Welcome to our dedicated page for Jazz Pharmaceuticals plc SEC filings (Ticker: JAZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jazz Pharmaceuticals plc filings document material events for an Ireland-domiciled biopharmaceutical issuer with Nasdaq-listed ordinary shares. Recent 8-K reports furnish quarterly and annual financial results, guidance, corporate presentations and product-level commentary for Xywav, Epidiolex, Modeyso and oncology launches.
The company’s filings also record clinical and regulatory disclosures for Ziihera (zanidatamab-hrii) and the HERIZON-GEA-01 program, board and committee changes, standard director compensation and indemnification arrangements, and settlement agreements involving patent and related commercial disputes. These records tie Jazz’s capital-market disclosures to its neuroscience and oncology portfolio, governance structure and material business events.
Jazz Pharmaceuticals plc director Bruce C. Cozadd reported an open-market sale of 6,000 Ordinary Shares of JAZZ on July 1, 2026 at an average price of $240.47 per share. The filing shows that Cozadd continues to directly hold 366,682 Ordinary Shares after this transaction.
According to the disclosure, the trade was executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025, meaning the timing was set in advance and was not a discretionary decision by the reporting person.
Jazz Pharmaceuticals EVP and Chief Commercial Officer Samantha Pearce reported a tax-related share disposition. On the vesting of previously granted restricted stock units, 2,527 ordinary shares were withheld at a price of $237.72 per share to cover tax obligations, a non-market transaction classified as a tax-withholding disposition.
After this event, Pearce directly held 47,911 ordinary shares. A footnote also notes that she acquired 166 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 29, 2026, reflecting routine employee share purchase activity separate from the tax withholding.
Jazz Pharmaceuticals plc reported a routine insider transaction by its President & CEO, Renee D. Gala. On June 30, 2026, 4,835 ordinary shares were withheld at $237.72 per share to cover tax obligations arising from the vesting of previously granted restricted stock units. This was a tax-withholding disposition, not an open-market sale. Following the transaction, Gala directly holds 147,361 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals EVP and CMO Robert Iannone reported a routine tax-related share disposition. On vesting of previously granted restricted stock units, 3,764 Ordinary Shares were withheld to satisfy tax obligations at $237.72 per share. After this withholding, he directly holds 85,107 Ordinary Shares.
Jazz Pharmaceuticals EVP & Chief Legal Officer Neena M. Patil had 2,678 Ordinary Shares withheld on June 30, 2026 to cover taxes from vesting restricted stock units. The shares were not sold on the open market but used to satisfy tax obligations.
After this tax-withholding disposition, Patil directly holds 48,871 Ordinary Shares. This type of transaction is routine for equity-based compensation and does not represent a discretionary purchase or sale decision.
Jazz Pharmaceuticals EVP & Chief Financial Officer Philip L. Johnson reported a routine tax-withholding transaction related to equity compensation. On the vesting of previously granted restricted stock units, 3,343 ordinary shares were withheld at $237.72 per share to satisfy tax obligations. After this disposition, he directly holds 56,431 ordinary shares. A footnote also notes he acquired 166 ordinary shares under a Section 423 employee stock purchase plan on May 29, 2026.
Jazz Pharmaceuticals submitted a Section 144 notice listing planned sales of Common Stock by an affiliate and recent dispositions. The filing lists three recent sales by Bruce Cozadd of 6,000 shares on 04/01/2026, 6,000 shares on 05/01/2026, and 6,000 shares on 06/01/2026. The filing also records previously issued stock options dated 02/26/2018 (1,335), 03/05/2018 (4,362), and 02/28/2019 (303).
Jazz Pharmaceuticals plc director Mark Douglas Smith reported an open-market sale of 1,157 ordinary shares at $230.55 per share. After this transaction, he directly holds 9,680 ordinary shares. According to a disclosed Rule 10b5-1 trading plan adopted on March 9, 2026, the sale occurred automatically and was not a discretionary trade.
Jazz Pharmaceuticals EVP & Chief Legal Officer Neena M. Patil reported an open-market sale of 1,200 ordinary shares on June 10, 2026 at $231.83 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan and occurred automatically. After this transaction, she directly holds 51,549 ordinary shares. A footnote also notes she acquired 123 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 29, 2026.